|
Ronghao Li Co-founder of Raven Biotechnologies, Inc. (South San Francisco), a company that discovers and develops monoclonal antibodies for cancer therapy. He has chaired corporate project management committee and led corporate partner projects. He leads a group of scientist working from discovery of candidate monoclonal antibodies through process development of mammalian cell production. Dr. Li has over 20 years of experiences in serum free culture of mammalian cells for therapeutic and research use. He also has rich working experiences in developing drugs in the fields of endocrinology, immunology, neuroscience and cancer therapy with tens of issued US patents and pending patent applications. Dr. Li graduated from Beijing Normal University and obtained M.S. and Ph.D degrees from Institute of Zoology, the Chinese Academy of Sciences. He did his postdoctoral training in Dr. Jennie P. Mather’s lab at Genentech, where Dr. Mather first developed serum free process for recombinant protein in CHO cells. Dr. Li has published five dozen peer reviewed scientific articles | 